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Background
Cow’s milk Oral Immunotherapy (CM-OIT) is still an
experimental treatment. The development of novel bio-
markers to predict the safety and efficacy of CM-OIT is
crucial to translate this treatment to common clinical
practice.
Objective
To analyze long-term changes in IgE and IgG4 epitope
binding profile during CM-OIT to identify safety and
efficacy biomarkers.
Methods
We studied 25 CM-allergic children at baseline, after
oral desensitization, and at 6, 12 and 24 months of fol-
low-up. Seven patients who refused CM-OIT were used
as controls. Patients were classified as low, moderate,
and high risk according to the number of allergic reac-
tions (safety), time required to achieve tolerance (effi-
cacy), and requirement of premedication. IgE and IgG4
peptide microarray immunoassay was performed using a
library of overlapping peptides of CM proteins.
Results
CM-OIT produced a rapid increase of IgG4-binding epi-
topes and slow decrease in IgE-binding epitopes. High risk
patients recognized a higher number of IgE-positive pep-
tides than low and moderate risk patients, with significant
increases in caseins at all the times studied. Similar but
less pronounced changes were observed for IgG4-positive
peptides. Clustering analysis grouped together the high
risk patients and we identified 13 regions of caseins signifi-
cantly different between groups of patients. Bioinformatics
analysis selected a set of 16 IgE-binding peptides at base-
line that predicted safety and efficacy of CM-OIT.
Conclusion
We developed a novel diagnostic approach based on a
set of IgE-binding peptides that can be used as biomar-
kers to predict the safety and efficacy of CM-OIT before
starting treatment.
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